Vertex Pharmaceuticals (VRTX) Net Cash Flow (2009 - 2026)

Vertex Pharmaceuticals has reported Net Cash Flow for 18 years, with the latest figure at $652.9 million in Q2 2026.

• On a quarterly basis, Net Cash Flow rose 172.72% year-over-year to $652.9 million in Q2 2026; TTM through Jun 2026 was $1.2 billion, a 270.01% increase from a year earlier, with the FY2025 full-year figure at $424.7 million, up 107.38% from the prior year.
• Net Cash Flow was $652.9 million for Q2 2026 at Vertex Pharmaceuticals, up from $457.4 million in the prior quarter.
• The five-year high for Net Cash Flow was $1.3 billion in Q4 2022, with the low at -$4.6 billion in Q2 2024.
• Average Net Cash Flow over 5 years is -$36.0 million, with a median of $348.4 million recorded in 2025.
• The sharpest annual moves came in 2022 and 2024: Net Cash Flow soared 558.1% in 2022, then sank 639.74% in 2024.
• Over 5 years, Net Cash Flow stood at $1.3 billion in 2022, then plunged by 159.63% to -$771.7 million in 2023, then grew by 18.54% to -$628.6 million in 2024, then jumped by 121.11% to $132.7 million in 2025, then soared by 392.01% to $652.9 million in 2026.
• The last three Net Cash Flow figures came in at $652.9 million (Q2 2026), $457.4 million (Q1 2026), and $132.7 million (Q4 2025), per Business Quant data.